Repository of the Max Delbrück Center for Molecular Medicine (MDC) in the Helmholtz Association

https://edoc.mdc-berlin.de/16437

Control of gene editing by manipulation of DNA repair mechanisms

Danner, E., Bashir, S., Yumlu, S., Wurst, W., Wefers, B., Kühn, R.

This is the final version of the accepted manuscript. The original article has been published in final edited form in:

Mammalian Genome

2017 AUG DD; 28(7-8): 262-274

2017 APR 03 (first published online: final publication)

Doi: 10.1007/s00335-017-9688-5

Publisher: Springer US

Publisher's notice

This is a post-peer-review, pre-copyedit version of an article published in *Mammalian Genome*. The final authenticated version is available online at: https://doi.org/10.1007/s00335-017-9688-5

Copyright © 2017 Springer Science+Business Media New York

Mammalian Genome special issue

Control of Gene Editing by Manipulation of DNA Repair Mechanisms

Eric Danner^{1*}, Sanum Bashir^{1, 2*}, Saniye Yumlu^{1, 2}, Benedikt Wefers^{3,4}, Ralf Kühn^{1,2}

- 1) Max-Delbrück-Centrum für Molekulare Medizin, Robert-Rössle-Str. 10, 13125 Berlin, Germany
- 2) Berlin Institute of Health, Kapelle-Ufer 2, 10117 Berlin, Germany
- 3) Deutsches Zentrum für Neurodegenerative Erkrankungen e. V. (DZNE), Feodor-Lynen-Str.
- 17, 81377 Munich, Germany
- 4) Institute of Developmental Genetics, Helmholtz Zentrum München, German Research Center for Environmental Health, 85764 Neuherberg, Germany

Author contact information

Sanum Bashir Email: sanum.bashir@mdc-berlin.de
Eric Danner Email: eric.danner@mdc-berlin.de
Saniye Yumlu Email: saniye.yumlu@mdc-berlin.de
Benedikt Wefers Email: benedikt.wefers@dzne.de
Ralf Kühn Email: ralf.kuehn@mdc-berlin.de

Manuscript correspondence

Ralf Kühn

Email: ralf.kuehn@mdc-berlin.de

Phone: +49 30 9406 2832

Keywords: CRISPR; Cas9; Gene editing; HR; HDR; NHEJ

^{*} equal contribution

Abstract

DNA double-strand breaks (DSBs) are produced intentionally by RNA guided nucleases to achieve genome editing through DSB repair. These breaks are repaired by one of two main repair pathways, classic non-homologous end joining (c-NHEJ) and homology-directed repair (HDR), the latter being restricted to the S/G2 phases of the cell cycle and notably less frequent. Precise genome editing applications rely on HDR, with the abundant c-NHEJ formed mutations presenting a barrier to achieving high rates of precise sequence modifications. Here, we give an overview of HDR- and c-NHEJ-mediated DSB repair in gene editing and summarize the current efforts to promote HDR over c-NHEJ.

1. Introduction

DNA double-strand breaks (DSBs) are among the most dangerous lesions for DNA, resulting in cancer or cell death if ineffectively unrepaired. DSBs occur spontaneously due to endogenous metabolic products such as reactive oxygen species or by exposure to exogenous agents such as irradiation or mutagenic reagents (Jackson and Bartek 2009) (Mladenov et al. 2016). Furthermore, programmed DSBs occur as normal developmental intermediates in meiosis of germ cells and for the specification of antigen receptors in lymphocytes (Baudat et al. 2013) (Alt et al. 2013). In order to maintain genome integrity and survival cells constantly express biochemical components for the recognition and repair of DSBs. These repair mechanisms can be utilized for gene editing by the induction of artificial, targeted DSBs in regions of interest using programmable, sequence-specific nucleases. The first generations of sequence-specific nucleases included zinc-finger nucleases (ZFN), meganucleases and TALEN (Urnov et al. 2010) (Boch 2011). In recent years the bacterial CRISPR/Cas9 nuclease system became the preferred gene editing method due to its efficiency and simplicity (Komor et al. 2016) (Hsu et al. 2014). (Hsu et al. 2014). Research involving DSBs formed from Cas9 is highlighted in this review as Cas9 has become the system of choice for most researchers. For the creation of DSBs by CRISPR/Cas9 two basic components are introduced into cells: the Cas9 nuclease and a short, single guide (sg)RNA which associates with Cas9. The first twenty nucleotides of guide RNAs direct Cas9 to the complementary DNA target sequence located upstream of an invariant 5'-NGG-3' (for SpCas9) protospacer adjacent motif (PAM) sequence. Correct pairing of the sgRNA to the DNA leads to DSB formation 3 bp upstream of the PAM site (Jinek et al. 2012) (Ran et al. 2013). The advantage of the CRISPR/Cas9 system is that new genomic sites can be easily targeted by modification of the sgRNA sequence and no changes are required for the Cas9 protein. The initial demonstration of CRISPR/Cas9 activity in mammalian cells in 2013 (Cong et al. 2013) (Mali et al. 2013), has been expanded

to edit the genome of somatic and germline cells in a wide range of species (Barrangou and Doudna 2016).

For genetic editing efficient DSB formation is but the first step in a two-step process. The actual sequence editing is performed by the cell's DSB repair machinery. Presently it is possible to dictate the site of gene editing by DSB formation but we have much less control on the outcome of DNA repair. Unfortunatly, often the native DSB repair outcomes do not meet specific experimental needs. In this article first we give an overview on the usage of homology-directed repair (HDR) and classic non-homologous end joining (c-NHEJ) mediated DSB repair for gene editing, and then summarize the efforts undertaken to promote HDR over c-NHEJ.

2. Harnessing DSB Repair Mechanisms for Gene Editing

Two main branches of DSB repair mechanisms exist in mammalian cells. These either process DSB ends by strand resection and initiate repair by homology-directed repair (HDR), or seek for the immediate protection of free ends through religation by non-homologous end joining (c-NHEJ) (Lieber 2010) (Fig. 1). While the c-NHEJ pathway operates throughout all phases of the cell cycle, HDR is restricted to the S and G2 phases when intact sister chromatids are available as ideal repair templates (Hustedt and Durocher 2016). During mitosis DSB repair is entirely shut down to guard the chromosomes against the fusion of telomeres (Orthwein et al. 2014). In the G1 phase and in resting cells, c-NHEJ repair is exclusive since HDR is silenced. Both pathways are active and competing for in the S/G2 phases. In summary, DSB induction in a population of cycling cells leads to a variety of edited alleles, with c-NHEJ as the dominant outcome.

Under natural conditions HDR is mediated by the homologous recombination (HR) pathway (Heyer et al. 2010) (San Filippo et al. 2008). HR uses the intact identical sequences of sister chromatids as template for the repair of DSB sites, and leads to the reconstitution of a wildtype allele. To achieve precise sequence modifications at targeted DSBs, the HR pathway can be hacked by providing an artificial DNA repair template which contains sequence regions homologous to the DSB ends. The sequence between the homologous ends, either an insertion or replacement, is then transferred into the targeted locus during HDR, enabling the generation of precisely modified 'knockin' alleles, e.g. for codon replacements or the insertion of reporter genes (Fig. 1). Large sequence insertions require the use of double-stranded, plasmid-based gene targeting vectors with homology regions of > 500 bp. Shorter sequence modifications can be introduced by using synthetic single-stranded DNA oligodeoxynucleotides (ssODN) as repair templates. Repair using ssODNs is mediated by a poorly defined mechanism designated as single-strand template repair (SST-R).

Alternatively to HDR, short resected DSB ends can be religated via stretches of a few complementary nucleotides through the mechanism of microhomology-mediated end joining (MMEJ) (Sfeir and Symington 2015). MMEJ is active in the S and G2 phases at lower levels than HR. Its mode of function is based on the alignment of microhomologies between the sequences at the broken DNA ends. Under natural conditions this type of repair results into small sequence deletions resembling the products of c-NHEJ. However, this is a distinct pathway and can be harnessed for targeted sequence insertion by providing DNA fragments which include short homology regions to the DSB ends (Fig. 1) (Sakuma et al. 2016). Using this PITCh (Precise Integration into Target Chromosomes) approach for gene addition obviates the laborious construction of gene targeting vectors with long homology regions. Although PITCh is not yet widely used, it has been shown as an efficient tool for the integration of large donor DNAs into target sites in human cells, silk worm embryos, frogs, and mice (Nakade et al. 2014) (Hisano et al. 2015) (Aida et al. 2016).

In contrast to HDR, the c-NHEJ pathway mediates the religation of DSB ends without the involvement of a repair template. Although some fraction of NHEJ repair events likely results in precisely reconstituted wildtype sequences, a fraction of cleaved sequences gain a random insertion or deletion of one or more nucleotides (Indels). Therefore, DSB repair by the error-prone c-NHEJ pathway is frequently used to generate Indels within coding regions, which often will cause a frameshift knockout mutation (Fig. 1). The formation of Indels is enriched at Cas9-mediated DSBs as any error-free religation reforms the original target site, which can then be re-cleaved. This cleavage-ligation loop proceeds until a mutation is formed or the nuclease is diluted or degraded.

NHEJ repair has been shown to frequently ligate exogenously provided DNA segments in-between the ends of DSBs. In this approach, designated as Non-Homology (NH) Targeting (He et al. 2016), the orientation of the inserted fragments is stochastic and cannot not be controlled. This stochastic insertion has been recently overcome by a modification in the technique that allows a high degree of preference in the insertion orientation (Suzuki et al. 2016). This Homology-Independent Targeted Integration (HITI) method was shown to be remarkably efficient in primary cells *in vitro* and *in vivo*, suggesting that c-NHEJ can be a method of choice for achieving targeted integrations in non-dividing cells. As expected for c-NHEJ repair events, the ligation of the fragment into the genome frequently results in Indels at one or both junctions.

DSB Repair Signaling and Pathway Choice

For many gene editing experiments the frequency of alleles repaired by HDR is often low, increasing and complicating experiments. This is due to the inherent dominance of c-NHEJ repair and therefore efforts for influencing the cell's choice of DSB repair often aim to suppress c-NHEJ, as well as to enhance HDR. This section gives an overview on the key molecules which execute DSB repair and regulate its pathway choice.

The initiation of DBS repair is identical for both c-NHEJ and HDR The ATM (ataxia telangiectasia mutated) protein kinase is a key initial regulator of the DNA damage response coordinates DSB repair (Fig. 2). ATM is activated by the MRN (Mre11-Rad50-Nibrin) complex and other factors at DNA breaks (Stracker and Petrini 2011) (Lavin et al. 2015). Upon monomerization and autophosphorylation, ATM phosphorylates Serine 139 of histone H2AX, forming yH2AX. The phosphorylated residue on yH2AX is recognized by MDC1, which in turn recruits more MRN complexes (Stucki et al. 2005). These further activate ATM and create a positive feedback loop driving the expansion of vH2AX chromatin domains into vH2AX foci (Nakamura et al. 2010). MDC1 becomes phosphorylated by ATM at its TQXF repeats and initiates downstream signaling by recruiting the E3 ubiquitin ligase RNF8 (Fig. 2) (Smeenk and Mailand 2016) (Schwertman et al. 2016). RNF8 and its E2 enzyme partner UBC13 polyubiquitinate the H1 linker histone (Thorslund et al. 2015). This further promotes the recruitment of the E3 ubiquitin ligase RNF168 that ubiquitinates histone H2A at Lysine 13 and 15 (Mattiroli et al. 2012). H2A-K15Ub together with dimethylated Lysine 20 of histone H4 (H4K20me2) are chromatin marks for the recruitment of the checkpoint protein 53BP1 (Fig. 2) (Fradet-Turcotte et al. 2013) (Zimmermann and de Lange 2014). The control of accumulation of 53BP1 determines if the DSB event is repaired by c-NHEJ, or through resection and subsequent HDR (Symington and Gautier 2011) (Panier and Durocher 2013) (Daley and Sung 2014) (Zimmermann and de Lange 2014).

The classical c-NHEJ pathway initiates with the localization of 53BP1 to a DSB and blocks 5' resectioning. 53BP1 blocks CtIP based resectioning (Bunting et al. 2010) and recruits Rif1, which further blocks resectioning and inhibits BRCA1 accumulation (Escribano-Díaz et al. 2013) (Zimmermann et al. 2013). Unresected ends allow Ku70/80 to bind, further inhibiting resection. Ku proteins form a scaffold and recruit DNA-PKcs, which then recruits end-processing factors (like Artemis) and the XRCC4/XLF/DNA Ligase-IV complex. The XRCC4/XLF factors stabilize and align the DNA fibers and DNA Ligase IV ligates the two strands (Waters et al. 2014). Repair of chemically or irradiation-induced DSBs is greatly complicated by the need to excise and repair damaged bases. However this will be left out of this review as DSBs from Cas9 nucleases form blunt ends with 5' phosphorylated DNA, the substrate for DNA Ligase IV. The ability to excise damaged bases and then ligate

noncomplementary strands has resulted in c-NHEJ being often thought of as a mutagenic process. However given a complimentary cut, such as created by Cas9 error-free events can be 75% or higher (Bétermier et al. 2014). Error-prone mutations that have previously been attributed to c-NHEJ are often a result of DSB resectioning and annealing through the similarly named but mechanistically distinct a-NHEJ.

The homologous recombination pathway requires the exclusion of 53BP1 and resection to occur. H2A is de-ubiquitinated upon mitotic entry so 53BP1 is excluded from the chromatin (Giunta et al. 2010). During the S/G2 phase, BRCA1 excludes Rif1 from the foci, and recruits CtIP and the MRN complex. This complex initiates a cleavage step which is then further 5'-resected by Exo1 (Symington and Gautier 2011) (Sartori et al. 2007) (Symington 2016). The resection extends 2-4 kb on each side of the DSB (Zakharyevich et al. 2010). The exposed single-stranded DNA (ssDNA) is quickly bound by RPA for protection. RPA is replaced by Rad51 through the action of BRCA2 and Rad52 to form a nucleofilament competent for homology search (Liu et al. 2011). The Rad51 filaments maintain the ssDNA in a B-form which has triplets open for Watson-Crick paring with complementary triplets in homologous duplex DNA. It should be noted that this review highlights only some of the key factors of the HR pathway and more complete reviews are available (Heyer et al. 2010) (San Filippo et al. 2008) (Symington and Gautier 2011) (Jasin and Rothstein 2013).

Alternative Non-Homologous End Joining pathways (a-)NHEJ encompass Microhomology-Mediated End Joining (MMEJ), Single Strand Annealing (SSA), and Theta-Mediated End Joining (Rodgers and McVey 2016). Once thought to only be a backup pathway, a-NHEJ can in some cases occur up to 10% of the frequency of c-NHEJ (Corneo et al. 2007). These repair events can result in deletions of various sizes, and only sometimes anneal and ligate through microhomologies. However, they always begin with the same resection steps as in homologous recombination, involving the MRE11 complex and CtIP. Resection can be <20 bp for microhomology or up to thousands of bps for SSA. The choice between a-NHEJ and HR comes from the inability of RPA to be replaced by Rad51 by Rad52/BRCA2. This limits the ssDNA to proceed through the HR pathway. Importantly, the extensive resection, when repaired by a-NHEJ, results in increased chromosomal translocation frequency, a major driver of human cancer (Deriano and Roth 2013).

- FIGURE 2 -

Manipulation of DSB repair pathways

The key molecules of the c-NHEJ pathway such as DNA Ligase-IV, Ku70/80, and DNA-PKcs have been targeted to transiently suppress c-NHEJ activity (Table 1). By transient suppression of c-NHEJ in cycling cells DSB repair can be biased in favor of HDR. SCR7 is a small molecule inhibitor that prevents the binding of Ligase IV to DNA and by this mean inhibits the ability of Ligase IV to join DSB ends (Srivastava et al. 2012). . Maruyama et al. used SCR7 to inhibit c-NHEJ repair for CRISPR/Cas9-induced DSBs in mammalian cell lines and mouse zygotes (Maruyama et al. 2015). The treatment of cells with SCR7 increased the rate of HDR events up to 19-fold. In a similar study DNA Ligase-IV was targeted in human and murine cell lines by SCR7, shRNA-mediated gene silencing, or by adenoviral (Ad) directed Ligase IV proteasomal degradation (Chu et al. 2015). A combined knockdown of Ku70/Ligase IV, SCR7 treatment, or Ad protein expression were all effective for c-NHEJ suppression and increased HR events in HEK293 cells up to 8-fold. However, SCR7 has shown unequal effectiveness when applied to other systems. It has been noted that its actual structure differs from the original description and furthermore its selectivity towards other DNA ligases has been questioned (Greco et al. 2016). The search for more potent and specific DNA Ligase-IV inhibitors will certainly continue since Ligase IV is a promising target in cancer therapy. A step into this direction was reported by Menchon et al. who identified a lead compound disrupting the interaction of the DNA Ligase-IV clamp domain to its binding partner XRCC4 (Menchon et al. 2016).

Various small molecule inhibitors against DNA-PK have been tested for suppression of c-NHEJ repair at CRISPR/Cas9-induced DSBs. Robert et al. confirmed previous results (Chu et al. 2015) on the suppression of Ligase IV and Ku70/80 to increase HDR. They additionally identified the DNA-PK inhibitors NU7441 and KU-0060648 effective for c-NHEJ suppression and resulted in increasing HDR for both double- and single-stranded DNA repair templates (Robert et al. 2015). Another approach antagonizes mammalian DNA-PK by depletion of its cofactor inositol hexakisphosphate (InsP6) using calmodulin inhibitors W7 and Chlorpromazine (Byrum et al. 2004). InsP6 depletion by these compounds reduces the binding of the Ku complex to DSBs affecting the recruitment of other c-NHEJ factors. Although not yet tested for its effect on CRISPR/Cas9-induced DSBs in mammalian cells, both inhibitors phenocopy the positive effect on HDR seen in Ku deletion strains of *Cryptococcus* fungi (Arras and Fraser 2016).

53BP1 is a key determinant of DSB repair pathway choice, promoting c-NHEJ by blocking DSB end resection. 53BP1 is therefore a prime target for interventions aiming to suppress c-c-NHEJ. Earlier studies of the role of 53BP1 in DSB repair used siRNA-mediated knockdown (Tang et al. 2013), the ectopic expression of dominant-negative (DN)53BP1 subdomains including the tandem Tudor domain (Xie et al. 2007) (Yoo et al. 2005), or 53BP1 inactivated

cell lines (Orthwein et al. 2015). Only recently have specific inhibitors against the 53BP1 protein become available. In a recent preprint, Canny et al. describe the development of `i53′ as a genetically coded high affinity peptide inhibitor of 53BP1 (Canny et al. 2016). i53 is a mutant ubiquitin with 7 amino acid substitutions that binds to the Tudor domain of 53BP1, preventing the recognition of the H2A-K15Ub ubiquitin mark for damaged chromatin. Expression of i53 suppresses the recruitment of 53BP1 at DSB sites in U2OS cells, leading to rates of HDR that are comparable to 53BP1 deficient cells. Combining both inhibitors i53 and NU7441, the rate of HDR was further increased (Canny et al. 2016).

Enrichment for HDR events

In addition to inhibiting the c-NHEJ pathway, considerable effort has focused on enhancing the efficiency of the HDR pathway. In the following part we will discuss different approaches that have been shown to promote HDR (Table 1).

Small molecules

RS-1, an enhancer of the single-strand DNA binding protein Rad51, was identified by library screening to support HR by stimulating the formation of active presynaptic Rad51 filaments (Jayathilaka et al. 2008). RS-1 was found to increase the insertion of reporter genes by 3-6 fold at CRISPR/Cas9-induced DSBs in HEK293 and U2OS cells. Coadministration of RS-1 and SCR7 had no additional effect on HDR (Pinder et al. 2015). Furthermore, RS-1 was recently shown in Cas9 microinjected rabbit embryos to improve HDR and knockin efficiencies by 25 fold *in vitro* and *in vivo* (Song et al. 2016). In the same study, the effect of SCR-7 was minimal, but the coinjection of mRNA for the overexpression of Rad51 had a comparable effect to the treatment with RS-1.

In a screen for regulators of DNA repair L755507 and Brefeldin A were identified as enhancers of HR in several mammalian cell lines at /Cas9-induced DSBs (Yu et al. 2015). The β 3-adrenergic receptor agonist L755507 increased HDR efficiency up to 3-fold when using a plasmid-based repair template and 9 fold when using a ssODN repair template. The addition of 0.1 μ M Brefeldin A, an inhibitor of the intracellular protein transport, showed a further enhancement in HR.

Synchronized Cas9 Delivery

The HR pathway is restricted to the S/G2 cell cycle phases to enable precise DSB repair by recombination of sister chromatids. Therefore, higher HR rates can be expected in a population of dividing cells enriched for the S/G2 phases by cell cycle synchronization. Lin et al. delivered pre-assembled Cas9/sgRNA ribonucleoprotein (RNP) complexes into synchronized primary

fibroblasts, HEK293, or human embryonic stem (ES) cells. These cells were blocked in S-phase by Aphidicolin, in M-phase by Nocodazole, or by both compounds sequentially (Lin et al. 2014). The timed delivery of RNPs into M-phase synchronized HEK cells led to a 4-fold increase in HR as compared to non-treated cells (38% vs 9%). In fibroblasts and ES cells Aphidicoline was more efficient. Yang et al. describes the synchronization of induced pluripotent stem (iPS) cells and neural progenitors using Nocodazole or ABT-751. They demonstrated a 3-6 fold increase for on-target gene editing in synchronized cells, and the edited iPS cells could be successfully differentiated into multiple lineages (Yang et al. 2016).

A complementary approach limits Cas9 activity to S/G2 phase of the cell cycle. In this study, Cas9 has been fused to a peptide from the Geminin protein which causes protein degradadation during the G1 phase of the cell cycle. The N-terminus of Geminin includes a destruction box motif that is recognized and tagged for degredation by the E3 ubiquitin ligase complex APC/Cdh1, active in the late M and G1 phase. Using this strategy, the rate of HR in HEK293 cells was found to be increased up to 87% as compared to unfused Cas9 (Gutschner et al. 2016). Using the same fusion in human iPS cells, Howden et al. did not observe increased HDR frequencies, but found a reduction of c-NHEJ-mediated Indels. This reduction in Indels facilitates the generation of heterozygous knockin cell lines that are free of mutations in the second, wildtype locus (Howden et al. 2016).

Reactivation of HDR in G1

The mechanistic basis for the suppression of HDR in the G1 phase of the cell cycle had long proven elusive. Subsequently it was not known whether HDR could be reactivated in this phase. Recently, the work of Orthwein et al. details the mechanism of HR containment in the S/G2 phase (Orthwein et al. 2015). They show how the cell cycle controst the interaction of BRCA1 with PALB2–BRCA2 and constrains BRCA2 function to the S/G2 phases. In the G1 phase the ubiquitination of PALB2 leads to its degradation while end resection at DSBs by CtIP is prevented by the lack of phosphorylation controlled by cyclin-dependent kinases. Hence the ectopic expression of a degradation resistant PALB2 mutant and a phosphomimetic mutant of CtIP, together with the inhibition of 53BP1 restores HDR in G1 cells at least to some extent. Alternatively to the inactivation of the 53BP1 by gene knockout, the ectopic expression of the i53 inhibitory peptide is equally efficient (Canny et al. 2016).

Structure of HDR Donors

In common practice templates used as HDR donors are either plasmid-based dsDNA or synthetic ssODNs. Plasmid-based vectors are suitable for introducing large sequence changes and insertions, and ssODNs are suitable for short (<50 nt) modifications. Typically ssODNs

are used with symmetric homology regions of 50-80 nt flanking each side of the DSB site, representing the forward or reverse strand of the target site. Nevertheless, an optimized ssODN design has been recently described in a study based on the interaction of the Cas9 protein with DSB ends, leading to improved rates of HDR (Richardson et al. 2016). The authors observed that in *in vitro* assays after DSB induction, Cas9 remains associated with the DNA for up to 5.5 hours. When dissociating from its target site Cas9 first releases the 3' end of the cleaved DNA strand that is non-complementary to the sgRNA. This led to the hypothesis that an ssODN complementary to the non-target strand could result into increased HDR rates. It was found that asymmetric ssODNs against the non-target strand with homology regions of 36 nt distal to the PAM site and of 91 nt proximal to the PAM site indeed result in almost 60% increase of HDR at multiple loci in HEK293 and K562 cells. In a follow-up study Liang et al. (Liang et al. 2017) observed that asymmetric ssODN donors that had short 30 nt 3'-homology and long 60 nt 5'-homology regions resulted in highest HDR efficiencies, regardless of which genomic strand was used. Contrary to Richardson et al. it appears that both DNA strands are resected upon the release of Cas9 and can initiate repair by annealing to appropriate ssODNs.

Another structural feature that can be modified in synthetic ssODNs is the replacement of the regular phosphodiester bonds by phosporothioate bond, increasing exonuclease resistance. Renaud et al. found that ssODNs with two phosporothioate bonds at both ends lead to higher knockin rates in U2OS cells and rodent embryos. Furthermore, since the homology regions of phosporothioate modified ssODNs can be kept short it is possible to increase the length of inserts up to 100 nt (Renaud et al. 2016). The efficiency of ssODNs is related to the distance between the mutation and DSB. Further, modulation of this distance can be used to generate heterozygous and homozygous knockins (Paquet et al. 2016).

Enrichment of Cells with HDR Alleles

The enrichment of cells that underwent HDR successfully is a potential alternative to increasing the absolute rate of HDR. The use of drug-selectable gene-targeting vectors for this purpose is long established and mandatory for gene targeting in mouse embryonic stem cells since the frequency of spontaneous HR, without assistance by site-specific nucleases, is very low (Hasty et al. 2000). The 'pop in, pop out' strategy described by Xi et al. (Xi et al. 2015) (Kühn and Chu 2015) uses the classic targeting vector design in a new way to improve the isolation of targeted clones obtained by CRISPR/Cas9 induced gene editing. Briefly, targeting vectors are used that include an expression cassette for a GFP reporter for the isolation of cells harboring a stable vector integration by fluorescence activated cell sorting (FACS). The use of a GFP cassette flanked with loxP recombination sites allows its removal in a subsequent transfection step with Cre recombinase, followed by the FACS enrichment of GFP- cells. This

approach, leaves a single loxP site in the target locus and so the authors also used a second targeting vector for the scarless removal of the selection cassette to introduce a single nucleotide replacement. Altogether, this method is a useful option for the isolation of cells harboring precisely modified alleles using CRISPR/Cas9-induced DSBs, but requires a second working step for removal of the marker gene.

A related, single step approach without marker removal has been described by Dever et al. for targeting of the β –globin (HBB) gene in human hematopoietic stem cells using AAV6 based HDR templates (Dever et al. 2016). The use of either GFP or a membrane bound truncated NGF receptor (tNGFR) allowed to enrich for cells undergoing HDR, reaching levels of up to 90%. Since in primary cells it is not possible to apply a second step for marker removal, HDR templates for correction of the HBB sickle cell mutation (G6V) introduced a functional HBB cDNA, followed by the tNGFR expression cassette.

Measurement and Quantification of DSB Repair Events

Following a DSB cells can and do follow numerous pathways to repair the lesion. This results in a multitude of genotypes within the cellular population for a single experiment. Whether working to optimize a specific outcome or simply understand an event's frequency for protocol design – i.e. picking an appropriate number of single cell derived colonies - one must be able to asses and quantify the population of repair outcomes following a cleavage event. This section provides a brief overview of some methods for measuring these events.

Knockout/Indel Analysis

A DNA break resulting in an Indel is a commonly sought for change to the genome. These Indels are considered knockouts when disrupting a gene and frequently introduced to produce a frameshift in a coding region. The variety of insertions and deletions can be considerable and outcomes difficult to predict *in silico* as repair comes through a combination of the c-NHEJ and a-NHEJ pathways. The T7 endonuclease assay (T7EI) is a simple way to gain a rough quantification of the overall Indel frequency. It is done through amplification of the Indel region, hybridization to a native sequence, and exposure to the T7EI mismatch cleaving endonuclease. Agarose gel-separated band intensities give an approximate quantification of alleles that contain an Indel (Wyvekens et al. 2015).

Often a more detailed characterization of the Indel is necessary. PCR amplicons of the cut-site of interest can be Sanger sequenced. The resulting mixture of sequencing traces can

be computationally deconvoluted by either TIDE (Brinkman et al. 2014) or CRISPR-ID (Dehairs et al. 2016). A functional readout of knockout effectiveness can be easily done if the target site encodes a surface expressing protein. In such cases FACS sorting provides a rapid and simple method for function based KO quantification and the enrichment of KO cells (Ren et al. 2016).

Knockin/HR Analysis

Optimization or quantification of HDR in a specific locus often begins by knockin of a fluorescent reporter into the locus of interest for rapid quantification by FACS (Dever et al. 2016) (Suzuki et al. 2016). This simple readout gives information about HDR events but no insight into the amount of Indels that concurrently formed. An easy readout to quantify both the HDR events and Indel events occurring in a population is to use the synthetic Traffic Light Reporter System. In this system an Indel can shift an out-of-frame RFP into the correct frame or repair a disrupted GFP by HDR (Certo et al. 2011) (Chu et al. 2015). In another approach cell lines with an integrated GFP reporter are utilized to asses HDR efficacy. GFP can be converted to BFP by a single nucleotide substitution by HR with ssODNs (Glaser et al. 2016) (Richardson et al. 2016). In this assay HDR events can be measured by the shift from GFP expression to BFP expression and NHEJ by the loss of fluorescence. Furthermore, Droplet Digital (dd)PCR is a method to distinguish and quantify HDR events vs Indel formation. This technique can be done rapidly for many samples or conditions, for any region of interest, and even if the HDR event only results in a single nucleotide substitution (Miyaoka et al. 2016).

Deep sequencing the region of interest provides the most detailed analysis of the repair events. The hardware and the software for amplicon profiling has become increasingly accessible for the specialist or non-specialist. Basic Indel profiling and simple HDR events, such as point mutations, can be easily analyzed by the Crispresso (Pinello et al. 2016) or Outknocker (Schmid-Burgk et al. 2014) online tool. For those more bioinformatically minded the R toolkit, CrispRvariant, has been developed (Lindsay et al. 2016) as well as Batch-GE (Boel et al. 2016).

Off-target mutations are often a point of concern, and perturbation of DNA repair pathways may alter the expected mutation frequency of off-targets. These off-target events can be monitored by PCR amplification of the predicted off-target locations (Haeussler et al. 2016). Genome sequencing is not sensitive for most off-target events at a population level but can be a comprehensive check on a single cell derived colony. Methods for comprehensive and rigorous off-target analysis using deep sequencing have been developed (Kim et al. 2016) (Tsai and Joung 2016).

RNA guided endonucleases such as CRISPR/Cas9 are revolutionizing the field of biology. The development and discovery of powerful ways to control the formation of DSBs requires an equal effort in DSB repair control. Despite efforts to improve HDR to increase genetic engineering possibilities, highly efficient gene editing by HDR is still challenging. In cycling cells progress has been made to shift the balance of DSB repair towards HDR. Further combination of conditions to suppress NHEJ (via 53BP1, DNA-PKcs or Ku70/80) and activate HDR (via CtIP, Rad51, Rad52, or Exo1) may be identified in future, to shift the balance of NHEJ/HDR repair more efficiently. In addition, negative regulators of the HDR response (reviewed by (Panier and Durocher 2013)) could represent new, yet unexplored targets for HDR enhancement. Improving the local assembly of regulatory molecules at the DSB of interest by e.g. fusion with the Cas9 protein may represent another, focused approach to promote HDR locally and minimize global interference with DSB repair pathways.

In quiescent or resting cells HDR based changes are dramatically more difficult as the HDR pathway is deactivated in the G0/G1 phase of the cell cycle. Since most cell types relevant for in vivo gene therapy are not cycling, current attempts focus on the subset of genetic defects which can be ameliorated by c-NHEJ mediated deletion of genomic sequences (Cox et al. 2015) (Maeder and Gersbach 2016) (Xue et al. 2016) (Long et al. 2016) (Nelson et al. 2016). The ability to induce HDR in G1 cells with defined factors could support the development of therapeutic applications which can be broadly applied for precise gene correction. The seminal work of Orthwein et al. identified 53BP1 suppression, and CtIP and PALB2 activation as key factors for the reactivation of HDR in G1 cells (Orthwein et al. 2015). Nevertheless, the reactivation of HDR in non-cycling, post-mitotic cells may require the identification and reversal of additional blockades - a field that deserves further exploration.

Methods that rely on DSB repair by c-NHEJ but allow the insertion of genetic sequences may be used in G0/G1 cells. Presently, the most efficient procedure to achieve targeted integration by c-NHEJ into single DSBs has been through the HITI approach (Fig. 1). This enables the integration of a defined DNA segment into a DSB in a preferred orientation, but includes sequence adaptions at the ends and often includes imprecise end joining at the religated junctions. Some regions of the genome may prove to be able to accomodate such mutations.

Alternatively to forming DSBs, the nicking of single strands may provide another precise, HDR-related approach with future potential. Here, ssODNs can be used as templates for the repair of single nicks induced by e.g. the Cas9^{D10A} nickase mutant. Nick repair is a safer alternative to DSBs as c-NHEJ is largely excluded (Kim et al. 2012) (Wang et al. 2012). Maizels and colleagues found that induced nicks are repaired by an alternative HDR pathway which is independent of the canonical HDR key factors Rad51 and BRCA2, which actually

inhibit this alternative pathway (Davis and Maizels 2011) (Davis and Maizels 2014) (Davis and Maizels 2016). This approach is promising and requires further study to increase the frequency of these precise repair events.

Taken together, there are many possibilities to improve these gene editing techniques to make them more efficient, precise, and safe for both *ex vivo* and *in vivo* applications. With the exponential pace of RNA guided nucleases adoption and utilization, this work is critically important and will be widely impactful.

Tables

Small molecules Brefeldin A L755507 ADP ribosylation β3-adrenergic receptor KU-0060648 W7/ chlorpromazine DNA-PKcs DNA-PKcs Knockdown shRNA ShRNA ShRNA ShRNA ShRNA ShRNA DNA Ligase IV Ku70 DNA-PKcs ShRNA ShRNA ShRNA		Enhancing HDR		Inhibiting NHEJ	
Small molecules Brefeldin A L755507 ADP ribosylation β3-adrenergic receptor KU-0060648 W7/ chlorpromazine DNA-PKcs DNA-PKcs DNA-PKcs Knockdown Character (a) 15507 ShRNA		Approach	Target	Approach	Target
L755507 β3-adrenergic receptor W7/ chlorpromazine DNA-PKcs		RS-1	Rad51	SCR7	DNA Ligase IV
Knockdown ShRNA S	Small molecules	Brefeldin A	ADP ribosylation	KU-0060648	DNA-PKcs
Knockdown ShRNA S		L755507	β3-adrenergic receptor	W7/ chlorpromazine	DNA-PKcs
Knockdown shRNA shRNA DNA-PKcs 53BP1 Overexpression cDNA expression				shRNA	DNA Ligase IV
Overexpression CDNA expression cDNA expressio	Knookdown			shRNA	Ku70
Overexpression CDNA expression Rad51 Rad51 S3BP1-Tudor Gene knockout S3BP1 Cas9-Geminin Palb2 (KR) Ctip (T847E) Prevent deactivation in G1 G1 Assymetric ssODN PTO modified ssODN Non-target strand 3' end Nuclease resistance Use of targeted reporter/marker genes (Pop in pop out) PITCh: usage of MMEJ for integration	KIIOCKUOWII			shRNA	DNA-PKcs
Overexpression CDNA expression CGNA ex				shRNA	53BP1
Cell cycle regulation Palb2 (KR) Ctip (T847E) Optimization of HDR template Alternative CDNA expression Rad51 Rad51 S3BP1-Tudor Gene knockout Faducing Cas9 expression in G1 cells Frevent deactivation in G1 G1 Non-target strand 3' end Nuclease resistance Use of targeted reporter/marker genes (Pop in pop out) PITCh: usage of MMEJ for integration				Adenoproteins	DNA Ligase IV
Cell cycle regulation Nocodazol Cas9-Geminin Palb2 (KR) Prevent deactivation in CtiP (T847E) Optimization of HDR template Alternative Consum a construction of CtiP (Tageted reporter/marker genes (Pop in pop out) PITCh: usage of MMEJ for integration Reducing Cas9 expression in G1 cells Frevent deactivation in G1 i53 53BP1-Tudor S3BP1 53BP1 53BP1 53BP1 53BP1 Frevent deactivation in G1 i53 53BP1 Frevent deactivation in G1 i53 SabP1 Frevent deactivation in G1 ibage of Mon-target strand 3 end Nuclease resistance	Overeverssion	cDNA expression	BRCA1	i53	53BP1
Cell cycle regulation Palb2 (KR) CtiP (T847E) Assymetric ssODN PTO modified ssODN Nuclease resistance Palb2 (KR) CtiP (T847E) Prevent deactivation in G1 cells For integration of HDR template SoDN PTO modified ssODN Nuclease resistance Use of targeted reporter/marker genes (Pop in pop out) PITCh: usage of MMEJ for integration	Overexpression	cDNA expression	Rad51	53BP1-Tudor	53BP1
Cell cycle regulation Palb2 (KR) CtiP (T847E) Prevent deactivation in G1 cells Optimization of HDR template Alternative Cas9-Geminin expression in G1 cells Prevent deactivation in G1 cells Is3 53BP1 Assymetric ssODN Non-target strand 3' end Nuclease resistance Use of targeted reporter/marker genes (Pop in pop out) PITCh: usage of MMEJ for integration				Gene knockout	53BP1
Cell cycle regulation Palb2 (KR) CtiP (T847E) Prevent deactivation in G1 cells Optimization of HDR template Alternative Cas9-Geminin expression in G1 cells Prevent deactivation in G1 cells Is3 53BP1 Non-target strand 3' end Nuclease resistance Use of targeted reporter/marker genes (Pop in pop out) PITCh: usage of MMEJ for integration		Negodovel	Reducing Cool		
regulation Palb2 (KR) CtiP (T847E) Prevent deactivation in G1 S3BP1 Optimization of HDR template Assymetric ssODN PTO modified soDN Nuclease resistance Use of targeted reporter/marker genes (Pop in pop out) PITCh: usage of MMEJ for integration			_		
Palb2 (KR) CtiP (T847E) Optimization of HDR template Assymetric ssODN PTO modified ssODN Nuclease resistance Use of targeted reporter/marker genes (Pop in pop out) PITCh: usage of MMEJ for integration	Cell cycle	Cass-Geillillill	expression in G1 cens		
Optimization of HDR template Use of targeted reporter/marker genes (Pop in pop out) Alternative CtiP (T847E) G1 Non-target strand 3` end nuclease resistance Use of targeted reporter/marker genes (Pop in pop out) PITCh: usage of MMEJ for integration	regulation				
Optimization of HDR template Assymetric ssODN PTO modified end Nuclease resistance Use of targeted reporter/marker genes (Pop in pop out) PITCh: usage of MMEJ for integration		Palb2 (KR)	Prevent deactivation in	:50	50004
HDR template PTO modified soDN Nuclease resistance Use of targeted reporter/marker genes (Pop in pop out) PITCh: usage of MMEJ for integration		CtiP (T847E)	G1	153	53BP1
HDR template PTO modified end Nuclease resistance Use of targeted reporter/marker genes (Pop in pop out) PITCh: usage of MMEJ for integration	Ontimization of	Assymetric ssODN	Non-target strand 3`		
Use of targeted reporter/marker genes (Pop in pop out) Alternative PITCh: usage of MMEJ for integration	•	PTO modified	end		
Alternative PITCh: usage of MMEJ for integration	HDR template	ssODN	Nuclease resistance		
Alternative PITCh: usage of MMEJ for integration					
- · · · · · · · · · · · · · · · · · · ·			,	op in pop out)	
approaches HITI: usage of NHEJ for integration	Alternative	PITCh: usage of M	MEJ for integration		
	approaches	HITI: usage of NHI	EJ for integration		

References

- Aida T, Nakade S, Sakuma T, et al (2016) Gene cassette knock-in in mammalian cells and zygotes by enhanced MMEJ. BMC Genomics 17:979. doi: 10.1186/s12864-016-3331-9
- Alt FW, Zhang Y, Meng F-L, et al (2013) Mechanisms of programmed DNA lesions and genomic instability in the immune system. Cell 152:417–429. doi: 10.1016/j.cell.2013.01.007
- Arras SDM, Fraser JA (2016) Chemical Inhibitors of Non-Homologous End Joining Increase Targeted Construct Integration in Cryptococcus neoformans. PloS One 11:e0163049. doi: 10.1371/journal.pone.0163049
- Barrangou R, Doudna JA (2016) Applications of CRISPR technologies in research and beyond. Nat Biotechnol 34:933–941. doi: 10.1038/nbt.3659
- Baudat F, Imai Y, de Massy B (2013) Meiotic recombination in mammals: localization and regulation. Nat Rev Genet 14:794–806. doi: 10.1038/nrg3573
- Bétermier M, Bertrand P, Lopez BS (2014) Is non-homologous end-joining really an inherently error-prone process? PLoS Genet 10:e1004086. doi: 10.1371/journal.pgen.1004086
- Boch J (2011) TALEs of genome targeting. Nat Biotechnol 29:135-136. doi: 10.1038/nbt.1767
- Boel A, Steyaert W, De Rocker N, et al (2016) BATCH-GE: Batch analysis of Next-Generation Sequencing data for genome editing assessment. Sci Rep 6:30330. doi: 10.1038/srep30330
- Brinkman EK, Chen T, Amendola M, van Steensel B (2014) Easy quantitative assessment of genome editing by sequence trace decomposition. Nucleic Acids Res 42:e168. doi: 10.1093/nar/gku936
- Bunting SF, Callén E, Wong N, et al (2010) 53BP1 inhibits homologous recombination in Brca1-deficient cells by blocking resection of DNA breaks. Cell 141:243–254. doi: 10.1016/j.cell.2010.03.012
- Byrum J, Jordan S, Safrany ST, Rodgers W (2004) Visualization of inositol phosphate-dependent mobility of Ku: depletion of the DNA-PK cofactor InsP6 inhibits Ku mobility. Nucleic Acids Res 32:2776–2784. doi: 10.1093/nar/gkh592
- Canny MD, Wan L, Fradet-Turcotte A, et al (2016) A genetically encoded inhibitor of 53BP1 to stimulate homology-based gene editing. Www Biorxivorg doi: https://doi.org/10.1101/060954.
- Certo MT, Ryu BY, Annis JE, et al (2011) Tracking genome engineering outcome at individual DNA breakpoints. Nat Methods 8:671–676. doi: 10.1038/nmeth.1648
- Chu VT, Weber T, Wefers B, et al (2015) Increasing the efficiency of homology-directed repair for CRISPR-Cas9-induced precise gene editing in mammalian cells. Nat Biotechnol 33:543–548. doi: 10.1038/nbt.3198
- Cong L, Ran FA, Cox D, et al (2013) Multiplex genome engineering using CRISPR/Cas systems. Science 339:819–823. doi: 10.1126/science.1231143
- Corneo B, Wendland RL, Deriano L, et al (2007) Rag mutations reveal robust alternative end joining. Nature 449:483–486. doi: 10.1038/nature06168

- Cox DBT, Platt RJ, Zhang F (2015) Therapeutic genome editing: prospects and challenges. Nat Med 21:121–131. doi: 10.1038/nm.3793
- Daley JM, Sung P (2014) 53BP1, BRCA1, and the choice between recombination and end joining at DNA double-strand breaks. Mol Cell Biol 34:1380–1388. doi: 10.1128/MCB.01639-13
- Davis L, Maizels N (2011) DNA nicks promote efficient and safe targeted gene correction. PloS One 6:e23981. doi: 10.1371/journal.pone.0023981
- Davis L, Maizels N (2014) Homology-directed repair of DNA nicks via pathways distinct from canonical double-strand break repair. Proc Natl Acad Sci U S A 111:E924–932. doi: 10.1073/pnas.1400236111
- Davis L, Maizels N (2016) Two Distinct Pathways Support Gene Correction by Single-Stranded Donors at DNA Nicks. Cell Rep 17:1872–1881. doi: 10.1016/j.celrep.2016.10.049
- Dehairs J, Talebi A, Cherifi Y, Swinnen JV (2016) CRISP-ID: decoding CRISPR mediated indels by Sanger sequencing. Sci Rep 6:28973. doi: 10.1038/srep28973
- Deriano L, Roth DB (2013) Modernizing the nonhomologous end-joining repertoire: alternative and classical NHEJ share the stage. Annu Rev Genet 47:433–455. doi: 10.1146/annurev-genet-110711-155540
- Dever DP, Bak RO, Reinisch A, et al (2016) CRISPR/Cas9 β-globin gene targeting in human haematopoietic stem cells. Nature 539:384–389. doi: 10.1038/nature20134
- Escribano-Díaz C, Orthwein A, Fradet-Turcotte A, et al (2013) A cell cycle-dependent regulatory circuit composed of 53BP1-RIF1 and BRCA1-CtIP controls DNA repair pathway choice. Mol Cell 49:872–883. doi: 10.1016/j.molcel.2013.01.001
- Fradet-Turcotte A, Canny MD, Escribano-Díaz C, et al (2013) 53BP1 is a reader of the DNA-damage-induced H2A Lys 15 ubiquitin mark. Nature 499:50–54. doi: 10.1038/nature12318
- Giunta S, Belotserkovskaya R, Jackson SP (2010) DNA damage signaling in response to double-strand breaks during mitosis. J Cell Biol 190:197–207. doi: 10.1083/jcb.200911156
- Glaser A, McColl B, Vadolas J (2016) GFP to BFP Conversion: A Versatile Assay for the Quantification of CRISPR/Cas9-mediated Genome Editing. Mol Ther Nucleic Acids 5:e334. doi: 10.1038/mtna.2016.48
- Greco GE, Matsumoto Y, Brooks RC, et al (2016) SCR7 is neither a selective nor a potent inhibitor of human DNA ligase IV. DNA Repair 43:18–23. doi: 10.1016/j.dnarep.2016.04.004
- Gutschner T, Haemmerle M, Genovese G, et al (2016) Post-translational Regulation of Cas9 during G1 Enhances Homology-Directed Repair. Cell Rep 14:1555–1566. doi: 10.1016/j.celrep.2016.01.019
- Haeussler M, Schönig K, Eckert H, et al (2016) Evaluation of off-target and on-target scoring algorithms and integration into the guide RNA selection tool CRISPOR. Genome Biol 17:148. doi: 10.1186/s13059-016-1012-2
- Hasty P, Abuin A, Bradley A (2000) Gene targeting, principles, and practice in mammalian cells. In: Gene Targeting: a practical approach. Oxford University Press, Oxford, pp 1–35

- He X, Tan C, Wang F, et al (2016) Knock-in of large reporter genes in human cells via CRISPR/Cas9-induced homology-dependent and independent DNA repair. Nucleic Acids Res 44:e85. doi: 10.1093/nar/gkw064
- Heyer W-D, Ehmsen KT, Liu J (2010) Regulation of homologous recombination in eukaryotes. Annu Rev Genet 44:113–139. doi: 10.1146/annurev-genet-051710-150955
- Hisano Y, Sakuma T, Nakade S, et al (2015) Precise in-frame integration of exogenous DNA mediated by CRISPR/Cas9 system in zebrafish. Sci Rep 5:8841. doi: 10.1038/srep08841
- Howden SE, McColl B, Glaser A, et al (2016) A Cas9 Variant for Efficient Generation of Indel-Free Knockin or Gene-Corrected Human Pluripotent Stem Cells. Stem Cell Rep 7:508–517. doi: 10.1016/j.stemcr.2016.07.001
- Hsu PD, Lander ES, Zhang F (2014) Development and applications of CRISPR-Cas9 for genome engineering. Cell 157:1262–1278. doi: 10.1016/j.cell.2014.05.010
- Hustedt N, Durocher D (2016) The control of DNA repair by the cell cycle. Nat Cell Biol 19:1–9. doi: 10.1038/ncb3452
- Jackson SP, Bartek J (2009) The DNA-damage response in human biology and disease. Nature 461:1071–1078. doi: 10.1038/nature08467
- Jasin M, Rothstein R (2013) Repair of strand breaks by homologous recombination. Cold Spring Harb Perspect Biol 5:a012740. doi: 10.1101/cshperspect.a012740
- Jayathilaka K, Sheridan SD, Bold TD, et al (2008) A chemical compound that stimulates the human homologous recombination protein RAD51. Proc Natl Acad Sci U S A 105:15848–15853. doi: 10.1073/pnas.0808046105
- Jinek M, Chylinski K, Fonfara I, et al (2012) A programmable dual-RNA-guided DNA endonuclease in adaptive bacterial immunity. Science 337:816–821. doi: 10.1126/science.1225829
- Kim D, Kim S, Kim S, et al (2016) Genome-wide target specificities of CRISPR-Cas9 nucleases revealed by multiplex Digenome-seq. Genome Res 26:406–415. doi: 10.1101/gr.199588.115
- Kim E, Kim S, Kim DH, et al (2012) Precision genome engineering with programmable DNA-nicking enzymes. Genome Res 22:1327–1333. doi: 10.1101/gr.138792.112
- Komor AC, Badran AH, Liu DR (2016) CRISPR-Based Technologies for the Manipulation of Eukaryotic Genomes. Cell. doi: 10.1016/j.cell.2016.10.044
- Kühn R, Chu VT (2015) Pop in, pop out: a novel gene-targeting strategy for use with CRISPR-Cas9. Genome Biol 16:244. doi: 10.1186/s13059-015-0810-2
- Lavin MF, Kozlov S, Gatei M, Kijas AW (2015) ATM-Dependent Phosphorylation of All Three Members of the MRN Complex: From Sensor to Adaptor. Biomolecules 5:2877–2902. doi: 10.3390/biom5042877
- Liang X, Potter J, Kumar S, et al (2017) Enhanced CRISPR/Cas9-mediated precise genome editing by improved design and delivery of gRNA, Cas9 nuclease, and donor DNA. J Biotechnol 241:136–146. doi: 10.1016/j.jbiotec.2016.11.011

- Lieber MR (2010) The mechanism of double-strand DNA break repair by the nonhomologous DNA end-joining pathway. Annu Rev Biochem 79:181–211. doi: 10.1146/annurev.biochem.052308.093131
- Lindsay H, Burger A, Biyong B, et al (2016) CrispRVariants charts the mutation spectrum of genome engineering experiments. Nat Biotechnol 34:701–702. doi: 10.1038/nbt.3628
- Lin S, Staahl BT, Alla RK, Doudna JA (2014) Enhanced homology-directed human genome engineering by controlled timing of CRISPR/Cas9 delivery. eLife 3:e04766. doi: 10.7554/eLife.04766
- Liu J, Ehmsen KT, Heyer W-D, Morrical SW (2011) Presynaptic filament dynamics in homologous recombination and DNA repair. Crit Rev Biochem Mol Biol 46:240–270. doi: 10.3109/10409238.2011.576007
- Long C, Amoasii L, Mireault AA, et al (2016) Postnatal genome editing partially restores dystrophin expression in a mouse model of muscular dystrophy. Science 351:400–403. doi: 10.1126/science.aad5725
- Maeder ML, Gersbach CA (2016) Genome-editing Technologies for Gene and Cell Therapy. Mol Ther J Am Soc Gene Ther 24:430–446. doi: 10.1038/mt.2016.10
- Mali P, Yang L, Esvelt KM, et al (2013) RNA-guided human genome engineering via Cas9. Science 339:823–826. doi: 10.1126/science.1232033
- Maruyama T, Dougan SK, Truttmann MC, et al (2015) Increasing the efficiency of precise genome editing with CRISPR-Cas9 by inhibition of nonhomologous end joining. Nat Biotechnol 33:538–542. doi: 10.1038/nbt.3190
- Mattiroli F, Vissers JHA, van Dijk WJ, et al (2012) RNF168 ubiquitinates K13-15 on H2A/H2AX to drive DNA damage signaling. Cell 150:1182–1195. doi: 10.1016/j.cell.2012.08.005
- Menchon G, Bombarde O, Trivedi M, et al (2016) Structure-Based Virtual Ligand Screening on the XRCC4/DNA Ligase IV Interface. Sci Rep 6:22878. doi: 10.1038/srep22878
- Miyaoka Y, Berman JR, Cooper SB, et al (2016) Systematic quantification of HDR and NHEJ reveals effects of locus, nuclease, and cell type on genome-editing. Sci Rep 6:23549. doi: 10.1038/srep23549
- Mladenov E, Magin S, Soni A, Iliakis G (2016) DNA double-strand-break repair in higher eukaryotes and its role in genomic instability and cancer: Cell cycle and proliferation-dependent regulation. Semin Cancer Biol 37-38:51–64. doi: 10.1016/j.semcancer.2016.03.003
- Nakade S, Tsubota T, Sakane Y, et al (2014) Microhomology-mediated end-joining-dependent integration of donor DNA in cells and animals using TALENs and CRISPR/Cas9. Nat Commun 5:5560. doi: 10.1038/ncomms6560
- Nakamura AJ, Rao VA, Pommier Y, Bonner WM (2010) The complexity of phosphorylated H2AX foci formation and DNA repair assembly at DNA double-strand breaks. Cell Cycle Georget Tex 9:389–397. doi: 10.4161/cc.9.2.10475
- Nelson CE, Hakim CH, Ousterout DG, et al (2016) In vivo genome editing improves muscle function in a mouse model of Duchenne muscular dystrophy. Science 351:403–407. doi: 10.1126/science.aad5143

- Orthwein A, Fradet-Turcotte A, Noordermeer SM, et al (2014) Mitosis inhibits DNA double-strand break repair to guard against telomere fusions. Science 344:189–193. doi: 10.1126/science.1248024
- Orthwein A, Noordermeer SM, Wilson MD, et al (2015) A mechanism for the suppression of homologous recombination in G1 cells. Nature 528:422–426. doi: 10.1038/nature16142
- Panier S, Durocher D (2013) Push back to respond better: regulatory inhibition of the DNA doublestrand break response. Nat Rev Mol Cell Biol 14:661–672. doi: 10.1038/nrm3659
- Paquet D, Kwart D, Chen A, et al (2016) Efficient introduction of specific homozygous and heterozygous mutations using CRISPR/Cas9. Nature 533:125–129. doi: 10.1038/nature17664
- Pinder J, Salsman J, Dellaire G (2015) Nuclear domain "knock-in" screen for the evaluation and identification of small molecule enhancers of CRISPR-based genome editing. Nucleic Acids Res 43:9379–9392. doi: 10.1093/nar/gkv993
- Pinello L, Canver MC, Hoban MD, et al (2016) Analyzing CRISPR genome-editing experiments with CRISPResso. Nat Biotechnol 34:695–697. doi: 10.1038/nbt.3583
- Ran FA, Hsu PD, Wright J, et al (2013) Genome engineering using the CRISPR-Cas9 system. Nat Protoc 8:2281–2308. doi: 10.1038/nprot.2013.143
- Renaud J-B, Boix C, Charpentier M, et al (2016) Improved Genome Editing Efficiency and Flexibility Using Modified Oligonucleotides with TALEN and CRISPR-Cas9 Nucleases. Cell Rep 14:2263–2272. doi: 10.1016/j.celrep.2016.02.018
- Ren J, Liu X, Fang C, et al (2016) Multiplex genome editing to generate universal CAR T cells resistant to PD1 inhibition. Clin Cancer Res Off J Am Assoc Cancer Res. doi: 10.1158/1078-0432.CCR-16-1300
- Richardson CD, Ray GJ, DeWitt MA, et al (2016) Enhancing homology-directed genome editing by catalytically active and inactive CRISPR-Cas9 using asymmetric donor DNA. Nat Biotechnol 34:339–344. doi: 10.1038/nbt.3481
- Robert F, Barbeau M, Éthier S, et al (2015) Pharmacological inhibition of DNA-PK stimulates Cas9-mediated genome editing. Genome Med 7:93. doi: 10.1186/s13073-015-0215-6
- Rodgers K, McVey M (2016) Error-Prone Repair of DNA Double-Strand Breaks. J Cell Physiol 231:15—24. doi: 10.1002/jcp.25053
- Sakuma T, Nakade S, Sakane Y, et al (2016) MMEJ-assisted gene knock-in using TALENs and CRISPR-Cas9 with the PITCh systems. Nat Protoc 11:118–133. doi: 10.1038/nprot.2015.140
- San Filippo J, Sung P, Klein H (2008) Mechanism of eukaryotic homologous recombination. Annu Rev Biochem 77:229–257. doi: 10.1146/annurev.biochem.77.061306.125255
- Sartori AA, Lukas C, Coates J, et al (2007) Human CtIP promotes DNA end resection. Nature 450:509–514. doi: 10.1038/nature06337
- Schmid-Burgk JL, Schmidt T, Gaidt MM, et al (2014) OutKnocker: a web tool for rapid and simple genotyping of designer nuclease edited cell lines. Genome Res 24:1719–1723. doi: 10.1101/gr.176701.114

- Schwertman P, Bekker-Jensen S, Mailand N (2016) Regulation of DNA double-strand break repair by ubiquitin and ubiquitin-like modifiers. Nat Rev Mol Cell Biol 17:379–394. doi: 10.1038/nrm.2016.58
- Sfeir A, Symington LS (2015) Microhomology-Mediated End Joining: A Back-up Survival Mechanism or Dedicated Pathway? Trends Biochem Sci 40:701–714. doi: 10.1016/j.tibs.2015.08.006
- Smeenk G, Mailand N (2016) Writers, Readers, and Erasers of Histone Ubiquitylation in DNA Double-Strand Break Repair. Front Genet 7:122. doi: 10.3389/fgene.2016.00122
- Song J, Yang D, Xu J, et al (2016) RS-1 enhances CRISPR/Cas9- and TALEN-mediated knock-in efficiency. Nat Commun 7:10548. doi: 10.1038/ncomms10548
- Srivastava M, Nambiar M, Sharma S, et al (2012) An inhibitor of nonhomologous end-joining abrogates double-strand break repair and impedes cancer progression. Cell 151:1474–1487. doi: 10.1016/j.cell.2012.11.054
- Stracker TH, Petrini JHJ (2011) The MRE11 complex: starting from the ends. Nat Rev Mol Cell Biol 12:90–103. doi: 10.1038/nrm3047
- Stucki M, Clapperton JA, Mohammad D, et al (2005) MDC1 directly binds phosphorylated histone H2AX to regulate cellular responses to DNA double-strand breaks. Cell 123:1213–1226. doi: 10.1016/j.cell.2005.09.038
- Suzuki K, Tsunekawa Y, Hernandez-Benitez R, et al (2016) In vivo genome editing via CRISPR/Cas9 mediated homology-independent targeted integration. Nature 540:144–149. doi: 10.1038/nature20565
- Symington LS (2016) Mechanism and regulation of DNA end resection in eukaryotes. Crit Rev Biochem Mol Biol 51:195–212. doi: 10.3109/10409238.2016.1172552
- Symington LS, Gautier J (2011) Double-strand break end resection and repair pathway choice. Annu Rev Genet 45:247–271. doi: 10.1146/annurev-genet-110410-132435
- Tang J, Cho NW, Cui G, et al (2013) Acetylation limits 53BP1 association with damaged chromatin to promote homologous recombination. Nat Struct Mol Biol 20:317–325. doi: 10.1038/nsmb.2499
- Thorslund T, Ripplinger A, Hoffmann S, et al (2015) Histone H1 couples initiation and amplification of ubiquitin signalling after DNA damage. Nature 527:389–393. doi: 10.1038/nature15401
- Tsai SQ, Joung JK (2016) Defining and improving the genome-wide specificities of CRISPR-Cas9 nucleases. Nat Rev Genet 17:300–312. doi: 10.1038/nrg.2016.28
- Urnov FD, Rebar EJ, Holmes MC, et al (2010) Genome editing with engineered zinc finger nucleases. Nat Rev Genet 11:636–646. doi: 10.1038/nrg2842
- Wang J, Friedman G, Doyon Y, et al (2012) Targeted gene addition to a predetermined site in the human genome using a ZFN-based nicking enzyme. Genome Res 22:1316–1326. doi: 10.1101/gr.122879.111
- Waters CA, Strande NT, Wyatt DW, et al (2014) Nonhomologous end joining: a good solution for bad ends. DNA Repair 17:39–51. doi: 10.1016/j.dnarep.2014.02.008

- Wyvekens N, Tsai SQ, Joung JK (2015) Genome Editing in Human Cells Using CRISPR/Cas Nucleases. Curr Protoc Mol Biol 112:31.3.1–18. doi: 10.1002/0471142727.mb3103s112
- Xie A, Hartlerode A, Stucki M, et al (2007) Distinct roles of chromatin-associated proteins MDC1 and 53BP1 in mammalian double-strand break repair. Mol Cell 28:1045–1057. doi: 10.1016/j.molcel.2007.12.005
- Xi L, Schmidt JC, Zaug AJ, et al (2015) A novel two-step genome editing strategy with CRISPR-Cas9 provides new insights into telomerase action and TERT gene expression. Genome Biol 16:231. doi: 10.1186/s13059-015-0791-1
- Xue H-Y, Zhang X, Wang Y, et al (2016) In vivo gene therapy potentials of CRISPR-Cas9. Gene Ther 23:557–559. doi: 10.1038/gt.2016.25
- Yang D, Scavuzzo MA, Chmielowiec J, et al (2016) Enrichment of G2/M cell cycle phase in human pluripotent stem cells enhances HDR-mediated gene repair with customizable endonucleases. Sci Rep 6:21264. doi: 10.1038/srep21264
- Yoo E, Kim BU, Lee SY, et al (2005) 53BP1 is associated with replication protein A and is required for RPA2 hyperphosphorylation following DNA damage. Oncogene 24:5423–5430. doi: 10.1038/sj.onc.1208710
- Yu C, Liu Y, Ma T, et al (2015) Small molecules enhance CRISPR genome editing in pluripotent stem cells. Cell Stem Cell 16:142–147. doi: 10.1016/j.stem.2015.01.003
- Zakharyevich K, Ma Y, Tang S, et al (2010) Temporally and biochemically distinct activities of Exo1 during meiosis: double-strand break resection and resolution of double Holliday junctions. Mol Cell 40:1001–1015. doi: 10.1016/j.molcel.2010.11.032
- Zimmermann M, de Lange T (2014) 53BP1: pro choice in DNA repair. Trends Cell Biol 24:108–117. doi: 10.1016/j.tcb.2013.09.003
- Zimmermann M, Lottersberger F, Buonomo SB, et al (2013) 53BP1 regulates DSB repair using Rif1 to control 5' end resection. Science 339:700–704. doi: 10.1126/science.1231573

Figure Legends

Figure 1 Utilizing DSB repair pathways for gene editing.

The repair of targeted DSBs induced by CRISPR/Cas9 in cycling cells can either religate or resect the DSB ends. End protection and religation is executed by the c-NHEJ repair pathway throughout all phases of the cell cycle. Gene knockout or disruption is achieved by the frequent insertion or deletion of nucleotides (Indel) during c-NHEJ repair. In the c-NHEJ-related HITI approach an exogenously provided DNA fragment is ligated in between the DSB ends in a directional manner. Resection of DSB ends in the S and G2 phase allows homology-directed repair (HDR). The HR pathway uses exogenous double-stranded or single-strand template repair (SST-R). Precise modifications or insertions are flanked by long (HR) or short (SST-R) regions of sequence homologies to the DSB ends and will be copied into the target locus. Alternatively, the PITCh approach utilizes MMEJ repair to achieve insertions with short homology sequences.

Figure 2 DSB signaling and main repair pathways

DSB repair signaling is initiated by the ATM protein kinase that activates histone H2AX and MDC1. Subsequently the E3 ubiquitin ligases RNF8 and RNF168 set the chromatin mark at K15 of histone H2A that serves to recruit 53BP1. The antagonism between BRCA1 and 53BP1 decides, under control of the cell cycle phase, on the resection or protection of DSB ends. This choice governs repair by the HR or c-NHEJ pathway. Molecules used to bias the outcome of DSB repair are shown (RS-1, i53, NU7441, SCR7).

Figure 1




Figure 2

